SCANCELL HOLDINGS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.875 GBX | +1.80% |
|
+7.92% | -5.95% |
| Mar. 26 | Scancell doses first patient in melanoma-focused trials | AN |
| Mar. 22 | Seneca Growth Capital announces tepid 2023 results | AN |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 80.96M 101M |
|---|---|---|---|---|---|
| Net income 2024 * | -14M -17.53M | Net income 2025 * | -14M -17.53M | EV / Sales 2024 * | - |
| Net Debt 2024 * | 3.88M 4.85M | Net Debt 2025 * | 14.94M 18.71M | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-5.49
x | P/E ratio 2025 * |
-6.53
x | Employees | 51 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.52% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +1.80% | ||
| 1 week | +7.92% | ||
| Current month | +10.71% | ||
| 1 month | +0.25% | ||
| 3 months | -17.71% | ||
| 6 months | -17.71% | ||
| Current year | -5.95% |
1 week
9.08
10.25
1 month
8.6010.25
Current year
8.6012.50
1 year
7.5918.30
3 years
7.5929.40
5 years
4.0029.40
10 years
0.1145.24
| Managers | Title | Age | Since |
|---|---|---|---|
Linda Durrant
CEO | Chief Executive Officer | 67 | 96-12-31 |
| Director of Finance/CFO | 38 | 23-08-28 | |
Fayaz Master
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 65 | 23-01-31 | |
Ursula Ney
BRD | Director/Board Member | 72 | 19-10-22 |
Linda Durrant
CEO | Chief Executive Officer | 67 | 96-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 9.875 | +1.80% | 214,593 |
| 24-05-09 | 9.7 | -1.77% | 577,398 |
| 24-05-08 | 9.875 | +5.05% | 762,868 |
| 24-05-07 | 9.4 | +2.73% | 322,579 |
| 24-05-03 | 9.15 | +0.55% | 1,054,095 |
Delayed Quote London S.E., May 10, 2024 at 11:35 am EDT
More quotes
Scancell Holdings plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is a developer of immunotherapies for the treatment of cancer and infectious diseases. The Company is building a pipeline of products by utilizing its four technology platforms: Moditope and ImmunoBody for vaccines and GlyMab and AvidiMab for antibodies. Its product pipeline includes Modi-1, Modi-2, SCIB1 & iSCIB1+, SCIB2 & iSCIB2, SCOV1 and SCOV2 (COVIDITY), as well as Anti-glycan antibodies. Modi-1, which targets citrullinated cancer antigens, is the first therapeutic vaccine candidate to emerge from Scancell's Moditope platform. Modi-2, which targets homocitrullinated cancer antigens, is the second therapeutic vaccine candidate from the Company's Moditope platform. Its lead ImmunoBody cancer vaccine, SCIB1, is being developed for the treatment of patients with metastatic melanoma. The COVIDITY program, focuses on the Company's COVID-19 vaccine candidates, SCOV1 and SCOV2.
Calendar
2024-05-14
- CIMT Meeting
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.0988
GBP
Average target price
0.2473
GBP
Spread / Average Target
+150.46%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -5.95% | 101M | |
| +17.96% | 44.96B | |
| +1.17% | 42.65B | |
| +48.77% | 41.85B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B |
- Stock Market
- Equities
- SCLP Stock
